InspireMD (NSPR)

• Market cap: $71.1M
• 1 day: -7.20%
• 5 days: -7.57%
• 1 month: -4.53%
• 3 months: -19.16%
• 6 months: -21.36%
• Year to date: -12.78%
• 1 year: -10.77%
• 5 years: -71.88%
• 10 years: -100.00%
• Sector: Healthcare
• Industry: Medical Devices

About: InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Employees: 66

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

17% more funds holding

Funds holding: 30 [Q4 2024] → 35 (+5) [Q1 2025]

4% more capital invested

Capital invested by funds: $33.4M [Q4 2024] → $34.7M (+$1.34M) [Q1 2025]

5.23% less ownership

Funds ownership: 48.74% [Q4 2024] → 43.51% (-5.23%) [Q1 2025]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $9K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 72% upside
• Avg. target: $4 72% upside
• High target: $4 72% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Adam Maeder

72% upside $4

Overweight Maintained

12 May 2025